£104.99

Nonalcoholic Fatty Liver Disease: New Insights

Internal Medicine

Price data last checked 101 day(s) ago - refreshing...

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

This is the most expensive it has ever been. Walk away.

£105 today · previous high £105 · all-time low £98

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 630 days • 630 data points (No recent data available)

Historical

Generating forecast...

Price Distribution

Price distribution over 630 days • 3 price levels

Days at Price

Current Price

Price Analysis

Most common price: £105 (512 days, 81.3%)

Price range: £98 - £105

Price levels: 3 different prices over 630 days

Description

Non-alcoholic fatty liver disease, or NAFLD, represents a spectrum of pathologic liver histologic findings ranging from the simple accumulation of fat, known as steatosis, to nonalcoholic steatohepatitis and cirrhosis. It is estimated that NAFLD in all of its forms would have a 20% prevalence worldwide, but the evidence suggests a higher rate for developed countries, exceeding 30% for the US general population. Major risk factors for NAFLD, such as ageing, obesity and insulin resistance, are projected to increase in the following decades, causing the prevalence and relevance of NAFLD to rise in the future. In obese populations and type 2 diabetes patients, the prevalence of this disease exceeds 70%. NAFLD has been called the ""silent epidemic"" for its lack of symptoms, relatively complex diagnosis and its deleterious effects. The association between NAFLD with cardiovascular diseases, energy metabolism disorders and polycystic ovarian syndrome has promoted the inclusion of this liver pathology within the metabolic syndrome. From a biochemical point of view, current evidence suggests the existence of a bidirectional causal relationship between NAFLD and oxidative stress, where various alterations energy metabolism and important inflammatory components are involved. An abnormal glucose and fatty acid metabolism lead to glucotoxicity and lipotoxicity, respectively, which promote oxidative stress through different pathways. Oxidative stress induces the expression of pro-inflammatory mediators, including transcription factors and cytokines, which trigger an immune activation, a key step in the transition from simple steatosis to steatohepatitis. An early diagnosis and optimal therapy are essential for NAFLD treatment. First-line treatment of NAFLD focuses on lifestyle changes. Weight reduction through an increase in physical activity and/or nutritional management is considered safe and effective, but pharmacological management of common comorbidities such as hyperglycemia, dyslipidemias and hypertension are also essential. The key role of oxidative stress in NAFLD pathophysiology suggests that antioxidant interventions based in natural substances such as polyphenols would be effective. Recently, it was shown that the antioxidant properties of these compounds are beyond their free radical scavenging. This book presents an update of research advances contributing to a better understanding of relevant clinical models of NAFLD, particularly, the disorder in energy metabolism and the role of oxidative stress. It also highlights the clinical and pathophysiological association between NAFLD and the metabolic syndrome, and presents an overview of current diagnosis and treatment and the future avenues for the management of this disease.

Product Specifications

Format: Hardcover
ASIN: 1634842170
Category: Books > Subjects > Health, Family & Lifestyle > Medical & Healthcare Practitioners > Internal Medicine
Domain: Amazon UK
Release Date: 01 January 2016
Listed Since: 04 November 2015

Barcode

No barcode data available

Nonalcoholic Fatty Liver Disease: New Insights

This is the most expensive it has ever been. Walk away.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Barcode

Similar Products You Might Like

The Impact of Obesity and Nutrition on Chronic Liver Diseases, An Issue of Clinics in Liver Disease (Volume 18-1) (The Clinics: Internal Medicine, Volume 18-1)

NASH and NAFLD, An Issue of Clinics in Liver Disease (Volume 22-1) (The Clinics: Internal Medicine, Volume 22-1)

Non-Alcoholic Fatty Liver Disease: A 360-degree Overview

Obesity, Fatty Liver and Liver Cancer: 1061 (Advances in Experimental Medicine and Biology, 1061)

Obesity, Fatty Liver and Liver Cancer: 1061 (Advances in Experimental Medicine and Biology, 1061)

Fatty Liver Disease: NASH and Related Disorders

Nutrition, Diet Therapy, and the Liver

Hepatic Steatosis: Clinical Risk Factors, Molecular Mechanisms and Treatment Outcomes (Hepatology Research and Clinical Developments)

Nutrition, Diet Therapy, and the Liver

Certain Herbal Extracts on Non Alcoholic Fatty liver development: Suppressive Effects of three plant extracts on non-alcoholic Fatty liver developments

Liver Pathophysiology: Therapies and Antioxidants

Hereditary Tyrosinemia: Pathogenesis, Screening and Management: 959 (Advances in Experimental Medicine and Biology, 959)

Molecular Pathology of Liver Diseases: 5 (Molecular Pathology Library, 5)

Liver Pathology, An Issue of Gastroenterology Clinics of North America (Volume 46-2) (The Clinics: Internal Medicine, Volume 46-2)

Autoimmune Liver Diseases: Perspectives from Japan

Liver Diseases: Advances in Treatment and Prevention: 137 (Falk Symposium, 137)

Metabolic Aspects of Chronic Liver Disease

Signaling Pathways in Liver Diseases

Atlas of the Liver (Atlas of Gastroenterology & Hepatology Series)

Liver Disease in Clinical Practice

Mitochondria in Liver Disease: 39 (Oxidative Stress and Disease)

Non-Alcoholic Steatohepatitis, An Issue of Clinics in Liver Disease (Volume 13-4) (The Clinics: Internal Medicine, Volume 13-4)

Springer - Autoimmune Liver Diseases: Perspectives from Japan

Peroxisome Proliferator-Activated Receptors (PPARs): Methods and Protocols: 952 (Methods in Molecular Biology)